Clinical trial

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

NCT02005120

Study summary

ClinicalTrials.gov

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Bevacizumab Normalized identity: bevacizumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention recombinant human endostatin Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2013-12-01

PhasePHASE2

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

BevacizumabDRUG · verified · RxNorm: bevacizumab

recombinant human endostatinDRUG

Sponsors & collaborators

Zhejiang Universitylead sponsor

Mapped research locations

HangzhouZhejiang, China2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02005120 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.